Amicus Therapeutics (FOLD) Projected to Post Quarterly Earnings on Wednesday

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) is projected to post its Q4 2024 quarterly earnings results before the market opens on Wednesday, February 19th. Analysts expect Amicus Therapeutics to post earnings of $0.10 per share and revenue of $147.88 million for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.12 on Friday, reaching $9.19. The company had a trading volume of 2,603,411 shares, compared to its average volume of 2,128,267. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.02. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company's fifty day moving average is $9.56 and its 200 day moving average is $10.41. The company has a market cap of $2.82 billion, a P/E ratio of -51.06, a PEG ratio of 1.51 and a beta of 0.61.

Analysts Set New Price Targets

FOLD has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday. JPMorgan Chase & Co. upped their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday. Finally, StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.20% of the company's stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.